Equity Overview
Price & Market Data
Price: $4.37
Daily Change: $0.00 / 0.00%
Daily Range: $4.02 - $4.60
Market Cap: $1,255,369,344
Daily Volume: 3,522,891
Performance Metrics
1 Week: 1.16%
1 Month: -5.82%
3 Months: -20.55%
6 Months: 37.42%
1 Year: 231.1%
YTD: -20.55%
Company Details
Employees: 99
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.